Johnson & Johnson seeks permission to conduct phase 3 trials for single-shot vaccine in India

The company sought an early meeting of the subject expert committee of the CDSCO to take a decision on its application, sources told PTI

Press Trust of India April 20, 2021 00:00:52 IST
Johnson & Johnson seeks permission to conduct phase 3 trials for single-shot vaccine in India

Representational image. PTI

New Delhi: Multinational pharma giant Johnson & Johnson has applied to India's drug regulator seeking permission to conduct phase-3 clinical trial of its single-dose COVID-19 vaccine in India as well as import licence, sources said.

They said the company has sought an early meeting of the subject expert committee on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) to take a decision on its application.

This comes close to the heels of the central government last week deciding to fast-track emergency approvals for all foreign produced coronavirus jabs that have been given a similar nod by the World Health Organization or regulators in the United States, Europe, Britain or Japan.

Such vaccines will be given emergency use approval mandating the requirement of post-approval parallel bridging clinical trial in place of conduct of local clinical trial under the provisions of the New Drugs and Clinical Trials Rules 2019, the health ministry had said.

According to sources, Johnson & Johnson had applied on 12 April in the Global Clinical Trial Division through the Sugam online portal, instead of applying to the biological division which deals with vaccines and other biologicals.

"Due to the technicalities involved, Johnson & Johnson has resubmitted its application on Monday," a source said.

The J&J vaccine can be stored for up to three months in a temperature between 2 and 8 degrees Celsius.

Johnson & Johnson's vaccine is a single-dose jab, whereas the three vaccines cleared by India so far are of doubles doses.

So far, two vaccines — Oxford/Astrazeneca vaccine COVISHIELD manufactured by Serum Institute in India and indigenously developed COVAXIN by Bharat Biotech — are being administered in India, while a third vaccine Sputnik V, developed in Russia and to be imported and sold in India by Dr Reddy's Laboratories, has also been approved by the Indian drug regulator.

The government, meanwhile, on Monday decided to expand its vaccination drive by allowing everyone above18 years of age eligible to be vaccinated from May 1 and permitted state governments, private hospitals and industrial establishments to procure the doses directly from manufacturers.

Updated Date:

also read

COVID-19 vaccine: Bharat Biotech commences direct supply of Covaxin to 14 states
India

COVID-19 vaccine: Bharat Biotech commences direct supply of Covaxin to 14 states

The Hyderabad-based firm has started supplying its COVID-19 vaccine to the states based on the allocations received by the central government

India pacer Jasprit Bumrah receives first dose of COVID-19 vaccine
First Cricket News

India pacer Jasprit Bumrah receives first dose of COVID-19 vaccine

Bumrah is expected to lead the Indian pace attack in the upcoming World Test Championship final against New Zealand and the subsequent away series in England.

Discussions on with Indian govt for expedited approval of COVID-19 vaccine, says Pfizer
India

Discussions on with Indian govt for expedited approval of COVID-19 vaccine, says Pfizer

CEO Albert Bourla said that Pfizer is aware that 'access to vaccines is critical'. "Unfortunately, our vaccine is not registered in India although our application was submitted months ago," the CEO added